Maria Fardis's Insider Trades & SAST Disclosures
Maria Fardis's most recent trade in CRISPR Therapeutics AG was a trade of 13,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 30, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Maria Fardis.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| CRISPR Therapeutics AG | Maria Fardis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 13,000 | 13,000 | - | - | Stock Option (Right to Buy) | |
| CRISPR Therapeutics AG | Maria Fardis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Iovance Biotherapeutics Inc | Maria Fardis | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 250,000 | 250,000 | - | - | Stock Option (right to buy) | |
| Iovance Biotherapeutics Inc | Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 33.12 per share. | 01 Jun 2020 | 1,894 | 298,786 (0%) | 0% | 33.1 | 62,729 | Common Stock |
| Iovance Biotherapeutics Inc | Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 32.00 per share. | 01 May 2020 | 1,894 | 300,680 (0%) | 0% | 32 | 60,608 | Common Stock |
| Iovance Biotherapeutics Inc | Maria Fardis | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.94 per share. | 01 Apr 2020 | 1,494 | 302,574 (0%) | 0% | 27.9 | 41,742 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges